ライフサイエンスコーパス: plexiform neurofibroma

1 land (seven with lymphadenopathy, one with a plexiform neurofibroma).

2 nalysis to measure the change in size of the plexiform neurofibroma.

3 include myeloid leukemia, optic glioma, and plexiform neurofibroma.

4 and to have NF1 and a clinically significant plexiform neurofibroma.

5 ically treated a patient with a debilitating plexiform neurofibroma.

6 l databases for children with orbitotemporal plexiform neurofibromas.

7 utaneous neurofibromas or clinically obvious plexiform neurofibromas.

8 and neurofibromatosis type 1 (NF1) -related plexiform neurofibromas.

9 firmed RUNX1 protein overexpression in human plexiform neurofibromas.

10 ues define the cell of origin for murine Nf1 plexiform neurofibroma and leverage this finding to deve

11 life, whereas loss in adulthood caused large plexiform neurofibromas and morbidity beginning 4 months

12 Major superficial plexiform neurofibromas and symptomatic spinal neurofibr

13 n S-100 positive Schwann cells of dermal and plexiform neurofibromas, and in endothelial cells of tum

14 Plexiform neurofibromas are common NF1 tumors carrying a

15 Plexiform neurofibromas are one of the most common tumor

16 Plexiform neurofibromas are pathognomonic of the disease

17 Plexiform neurofibromas are peripheral nerve sheath tumo

18 Dermal and plexiform neurofibromas are peripheral nerve sheath tumo

19 Plexiform neurofibromas are slow growing benign tumors t

20 Plexiform neurofibromas are slow-growing chemoradiothera

21 ptic pathway gliomas (OPGs) and orbitofacial plexiform neurofibromas are two of the more common ophth

22 Dermal and plexiform neurofibromas as well as malignant peripheral

23 with neurofibromatosis type 1 and inoperable plexiform neurofibromas benefited from long-term dose-ad

24 Patients commonly present with plexiform neurofibromas, benign but debilitating growths

25 es were established from 10 dermal and eight plexiform neurofibromas by selective subculture using gl

26 (NF-1), malignant transformation of internal plexiform neurofibromas carries a poor prognosis, in par

27 Previous studies found that plexiform neurofibroma formation in a mouse model requir

28 urine models that closely recapitulate human plexiform neurofibroma formation indicate that tumorigen

29 In mouse models of plexiform neurofibroma formation, Nf1 haploinsufficient

30 dies implicating the hematopoietic system in plexiform neurofibroma genesis, delineate the physiology

31 indicated a role for the microenvironment in plexiform neurofibroma genesis.

32 Plexiform neurofibromas have an intermediate range of le

33 Benign plexiform neurofibromas in NF1 patients can transform sp

34 Imatinib mesylate could be used to treat plexiform neurofibromas in patients with NF1.

35 the volume burden of clinically significant plexiform neurofibromas in patients with NF1.

36 val overgrowth is caused by the formation of plexiform neurofibromas in the connective tissue of the

37 cursors (SCP), which have been implicated in plexiform neurofibroma initiation.

38 Extent of orbitotemporal plexiform neurofibroma involvement was assessed clinical

39 of Nf1 resulted in the development of small plexiform neurofibromas late in life, whereas loss in ad

40 Orbitotemporal plexiform neurofibroma location was classified as isolat

41 Thus, the plexiform neurofibroma microenvironment involves a tumor

42 that mast cells underpin inflammation in the plexiform neurofibroma microenvironment of neurofibromat

43 delineate hematopoietic contributions to the plexiform neurofibroma microenvironment, and highlight a

44 han half of NF1 children with orbitotemporal plexiform neurofibromas, most commonly because of ptosis

45 ngineered mouse model that accurately models plexiform neurofibroma-MPNST progression in humans would

46 pe with neither externally visible cutaneous/plexiform neurofibromas nor other tumors.

47 , and facial structures (orbital-periorbital plexiform neurofibroma [OPPN]) can result in significant

48 Although plexiform neurofibroma (PN) is thought to represent a be

49 irtually pathognomonic finding of NF1 is the plexiform neurofibroma (PN), a benign, likely congenital

50 Plexiform neurofibromas (PNs) involving the eyelid, orbi

51 for sensitive measurement of orbitotemporal plexiform neurofibroma size, and larger volumes were ass

52 viable therapeutic options for patients with plexiform neurofibromas that cannot be surgically remove

53 eurofibromatosis type 1 (NF1) develop benign plexiform neurofibromas that frequently progress to beco

54 had neurofibromatosis type 1 and inoperable plexiform neurofibromas to determine the maximum tolerat

55 In addition, malignant progression of plexiform neurofibromas to malignant peripheral nerve sh

56 nt coincides with enhanced susceptibility to plexiform neurofibroma tumorigenesis.

57 tients with NF1 have cutaneous, diffuse, and plexiform neurofibromas, tumors comprised primarily of S

58 0%; 95% CI, 0%-7%) had discrete cutaneous or plexiform neurofibromas, typical NF1 osseous lesions, or

59 l subjects with amblyopia had orbitotemporal plexiform neurofibroma volumes greater than 10 mL.

60 Amblyopia secondary to the orbitotemporal plexiform neurofibroma was present in 13 subjects (62%)

61 e or decrease from baseline in the volume of plexiform neurofibromas) was monitored by using volumetr

62 reatment of neurofibromatosis type 1-related plexiform neurofibromas, which are characterized by elev